New/emerging psychoactive substances and associated psychopathological consequences - Corrigendum.

Schifano, F; Napoletano, F; Chiappini, S; Guirguis, A; Corkery, J M; Bonaccorso, S; Ricciardi, A; Scherbaum, N; Vento, A

Schifano, F; Napoletano, F; Chiappini, S; Guirguis, A; Corkery, J M; Bonaccorso, S; Ricciardi, A; Scherbaum, N; Vento, A.

Afiliação

Schifano F; Psychopharmacology, Drug Misuse, and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK.
Napoletano F; Homerton University Hospital, London, UK.
Chiappini S; Psychopharmacology, Drug Misuse, and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK.
Guirguis A; Swansea University Medical School, Institute of Life Sciences 2, Swansea University, Singleton Park, Swansea, Wales.
Corkery JM; Psychopharmacology, Drug Misuse, and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK.
Bonaccorso S; Camden and Islington NHS Mental Health Foundation Trust, London, UK.
Ricciardi A; Camden and Islington NHS Mental Health Foundation Trust, London, UK.
Scherbaum N; Department of Mental Health, ASL Roma 1, Rome, Italy.
Vento A; LVR-Klinikum Essen, Klinik für Psychiatrie und Psychotherapie, University of Duisburg-Essen, Essen, Germany.

Psychol Med ; 51(1): 43, 2021 01.

Article em En | MEDLINE | ID: mdl-31511097

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Psychol Med Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google